Glass vial with increased chemical stability

1. A glass vial, comprising: a base and a vial opening, the base comprising a boron-containing multicomponent glass, the glass vial holding a liquid active pharmaceutical ingredient formulation, the glass vial having a total volume of <4.5 mL, a filling level of the glass vial with the active pharmaceutical ingredient formulation is not more than 0.25 and a concentration of boron ions, measured at a measurement site below a plane of a middle of the glass vial using a concentration depth profile at a depth in a range from 10 to 30 nm, has a value, averaged over measurements of the concentration depth profile, that has an excess increase of not more than 30% compared to a concentration of boron ions measured using a concentration depth profile at a depth in a range from 10 to 30 nm with a measurement site in the plane of the middle of the glass vial, where the position of the plane of the middle of the glass vial is determined from an underside of the base of the glass vial in a direction of the vial opening.

2. The glass vial of claim 1 , wherein the concentration of boron ions, measured at the measurement site below the plane of the middle of the vessel using the concentration depth profile at the depth in the range from 10 to 30 nm, has a value, averaged over the measurements of the concentration depth profile, that has an excess increase of not more than 25% compared to the concentration of boron ions measured using the concentration depth profile at the depth in the range from 10 to 30 nm with the measurement site in the plane of the middle of the vessel.

3. The glass vial of claim 1 , wherein the concentration depth profile assumes a plateau value for boron ions from a depth of 150 nm downward.

4. The glass vial of claim 1 , wherein the glass of an inner wall of the glass vial is monophasic down to a depth of at least 200 nm.

5. The glass vial of claim 1 , wherein a surface of an inner wall of the glass vial at least one of does not have any coating or has not been etched.

6. The glass vial of claim 1 , wherein the liquid active pharmaceutical ingredient formulation contains at least one of a therapeutic protein, a monoclonal antibody, or a vaccine.

7. The glass vial of claim 1 , further comprising a seal.

8. The glass vial of claim 7 , wherein the seal is a sterile seal.

9. The glass vial of claim 1 , further comprising a side wall connected to the base, the glass comprising SiO 2 , the glass at the base at an inner wall has a composition having a higher SiO2 content than at the side wall and at a transition of the side wall to the base.

10. The glass vial of claim 9 , wherein a concentration of silicon ions, measured at a measurement site on an inside of the base of the glass vial using a concentration depth profile at a depth in a range from 5 to 15 nm, has a value, averaged over measurements of the concentration depth profile, that has an excess increase of at least 10% compared to a concentration of silicon ions measured using a concentration depth profile at a depth in a range from 5 to 15 nm with a measurement site in the plane of the middle of the glass vial.

11. The glass vial of claim 9 , wherein a concentration of sodium ions, measured at a measurement site on an inside of the base using a concentration depth profile at a depth in a range from 5 to 15 nm, has a value, averaged over measurements of the concentration depth profile, that has a decrease at least by a factor of 1.5 compared to a concentration of sodium ions measured using a concentration depth profile at a depth in a range from 5 to 15 nm with a measurement site in the plane of the middle of the glass vial.

12. The glass vial of claim 9 , wherein the concentration of boron ions, measured at a measurement site on an inside of the base using a concentration depth profile at a depth in a range from 10 to 30 nm, has a value, averaged over measurements of the concentration depth profile, that has a decrease at least by a factor of 3 compared to a concentration of boron ions measured using a concentration depth profile at a depth in a range from 10 to 30 nm with a measurement site in the plane of the middle of the glass vial.

13. The glass vial of claim 9 , wherein a surface of an inner wall of the glass vial at least one of has no coating or has not been etched.

14. The glass vial of claim 9 , wherein the glass of an inner wall of the glass vial is monophasic down to a depth of at least 200 nm in a near-base wall region.

15. The glass vial of claim 9 , wherein the liquid active pharmaceutical ingredient formulation comprises at least one of a therapeutic protein, a monoclonal antibody, or a vaccine.

16. The glass vial of claim 9 , wherein the filling level is not more than 0.125.

17. The glass vial of claim 1 , wherein the filling level is not more than 0.125.

18. The glass vial of claim 1 , wherein the glass vial has a nominal volume in a range from 1 mL to 2 mL.

19. A glass vial, comprising: a base, a side wall connected to the base, and a vial opening, the base and the side wall comprising a multicomponent glass, the glass vial holding a liquid active pharmaceutical ingredient formulation, the glass comprising SiO 2 , the glass vial having a total volume of <4.5 mL, a filling level of the glass vial with the active pharmaceutical ingredient formulation is not more than 0.25, the glass at the base at an inner wall has a composition having a higher SiO 2 content than at the side wall and at a transition of the side wall to the base.